New proprietary vaccine technology platform is said to have the potential to offer significant economic advantages to vaccine producers
Microbix Biosystems has announced filing of a patent for a new proprietary vaccine technology platform that it says has the potential to offer significant economic advantages to vaccine producers.
The company filed for the patent, with the intent of establishing exclusive rights on a global basis, after successfully concluding feasibility studies.
Its new technology is the result of nearly three years of development work, reports William J Gastle, president and CEO, "and is the second potential large market biologic to be advanced to the licensing stage since ThromboClear, which was successfully partnered in 2002." Gastle said this technology has the potential to further diversify Microbix's future revenue stream and that the company is now in the process of assembling the data necessary to commence discussions in the autumn with potential pharmaceutical partners interested in licensing the technology. The news follows earlier reports by the company that it would be making an announcement in the third quarter about a second large market product in its pipeline.
Further news will be issued as the size and timing of the opportunity is established, Gastle said.
Microbix specialises in developing and manufacturing tissue culture- derived biologicals for an emerging world market for biotherapeutic drugs and vaccines.
It makes reagents for building diagnostic products and tools used in biotechnology research.
It claims expertise in advanced culture, purification and process validation technologies.
Its objective during the next decade is to become a major force in what is expected to be a multi- billion generic biotherapeutics market in North America.
